# Progress Note 02 — Focused Visit (Intermediate follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Abraham Lincoln (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI001-SYN
- Date: 2026-08-11
- Fictional facility: St. Posthumous Health Center
- Fictional author: Elena Marquez, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Intermediate follow-up)

## Chief complaint

Six-week depression treatment follow-up. **S**

## History of present illness

Mr. Lincoln returns six weeks after starting sertraline 50 mg daily for a moderate depressive episode. His mood is brighter on most days, and he is enjoying his work again. He is back at court on his usual schedule and writes letters to friends two or three times a week. He falls asleep within half an hour and wakes once a night, compared with the broken sleep he described at intake, and his concentration on long briefs is better. Mild nausea in the first two weeks settled by the third week. He has had no headache, diarrhea, restlessness, or sexual side effects. He misses about one dose every two weeks. He has had no suicidal thoughts since the intake visit and still carries his safety plan. He drinks no alcohol. He saw Dr. Natarajan of psychiatry this morning. **S**

| Element | Detail |
|---|---|
| Interval change | Mood brighter on most days; back to court work and letters to friends |
| Sleep | Asleep within half an hour; wakes once a night |
| Medication tolerance | Nausea resolved by week three; no other adverse effects |
| Adherence | Misses about one dose every two weeks |
| Safety | No suicidal thoughts since intake; safety plan carried |
| PHQ-9 | 9, down from 14 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy improving; no weight change of note |
| Gastrointestinal | Negative | Early nausea resolved; no diarrhea, heartburn, or bleeding |
| Genitourinary | Negative | No sexual side effects |
| Neurological | Negative | No headache, tremor, or restlessness |
| Psychiatric | Positive | Low mood easing but not gone; sleep and concentration better; no suicidal thoughts, elevated mood, or racing thoughts |

5 systems reviewed. **S**

## Current medications

- Sertraline 50 mg oral tablet, one tablet by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 116/72 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.8 °C; oxygen saturation 99% on room air; weight 82.4 kg; BMI 22.1 kg/m². All vital signs are synthetic.

Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]: 9. All results are synthetic.

## Change since baseline

- Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]: 14 at baseline, 9 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Tall, neatly dressed, comfortable, and engaged |
| Mental status | Alert and oriented; mood "better, not yet myself"; affect mildly constricted but brighter and reactive, with humor; thought process linear; no suicidal ideation or psychotic features; insight and judgment good |
| Neurological | No tremor; gait normal |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Major depressive disorder, single episode, moderate, with partial response at six weeks** (F32.1). The PHQ-9 has fallen from 14 to 9, a 36 percent reduction: a partial response that is still short of the 50 percent reduction that defines response, but improving steadily on a well-tolerated dose. Psychiatry agrees with the diagnosis and found no bipolar or psychotic features. Suicide risk remains low, with no ideation since intake and the protective factors from the intake assessment unchanged. **S**
   - Continue sertraline 50 mg daily, as Dr. Natarajan advised.
   - Increase to 100 mg if the PHQ-9 is not below 5 at the twelve-week review.
   - Nurse telephone check with a PHQ-9 in about four weeks.
   - Collaborative safety plan reviewed and unchanged; 988 Suicide & Crisis Lifeline and the clinic number confirmed.
   - Continue the two valued activities each week; psychotherapy remains available if he wants it.
   - Avoid regular NSAIDs, tramadol, triptans, St John's wort, and dextromethorphan without checking first, because of interactions with sertraline.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | PHQ-9 | Baseline, then at least monthly during acute treatment; every 2 to 4 weeks in continuation | Completed today | 9, down from 14 at intake (36 percent): partial response, not yet the 50 percent reduction that defines response |
| Survey | PHQ-9 at four weeks | At least monthly during acute treatment | Deferred | Not done: the care plan set the first review at six weeks, so no score was taken at four weeks, a deviation from the protocol. No harm resulted: today's score has fallen 5 points and he has no suicidal thoughts. Corrective action: a nurse telephone PHQ-9 in about four weeks, so the seven weeks to the twelve-week review are not left unmeasured |
| Survey | Suicide risk reassessment (C-SSRS Since Last Visit and PHQ-9 item 9) | Every visit during active treatment | Completed today | No suicidal thoughts, intent, plan, or behavior since the intake visit; PHQ-9 item 9 scored 0. Protective factors unchanged. Collaborative safety plan reviewed with him: he carries his copy and has 988 and the clinic number saved |
| Medication safety | Sertraline tolerability check two weeks after starting | 2 weeks after starting and after each dose change | Deferred | Not done: no contact was scheduled between the intake visit and today, a deviation from the protocol, which also calls for closer contact in the first weeks of an antidepressant. No harm resulted judging by today's review: the mild nausea settled by the third week, and he has had no restlessness, agitation, or suicidal thoughts. Corrective action: a nurse telephone check one to two weeks after any future start or dose change is now in his plan |
| Medication safety | Adherence and adverse-effect review | Every visit during active treatment | Completed today | Misses about one dose every two weeks; nausea resolved; no headache, diarrhea, tremor, restlessness, sexual side effects, bruising, or bleeding |
| Survey | Mood Disorder Questionnaire (bipolar screen) | Once at the initial depression workup | Deferred | Not given at intake, a deviation from the protocol. Dr. Natarajan's interview today found no past periods of elevated or irritable mood, reduced need for sleep, or racing thoughts, so bipolar disorder is not suspected, and no harm resulted: he has had no activation on sertraline. The questionnaire will be used if hypomanic features appear |
| Examination | Weight, BMI, and blood pressure | Baseline metabolic review, then with each tolerability check | Completed today | Weight 82.4 kg, up 0.4 kg since intake; BMI 22.1; blood pressure 116/72 mmHg |
| Examination | Mental status examination | Every visit | Completed today | Brighter, reactive affect; linear thinking; no suicidal ideation or psychotic features |
| Laboratory | Drug levels and metabolic laboratory monitoring | Lithium, valproate, carbamazepine, or second-generation antipsychotic therapy | Not indicated | Sertraline monotherapy needs no routine laboratory monitoring |
| Examination | Abnormal Involuntary Movement Scale (AIMS) | Every 6 months on antipsychotic therapy | Not indicated | No antipsychotic medicine |
| Referral | Psychiatry consultation | At diagnosis, as the care plan specifies | Completed today | Seen by Dr. Natarajan this morning. She agrees with the diagnosis and with sertraline monotherapy, found no bipolar or psychotic features, and judged acute suicide risk low |
| Self-management | Behavioral activation: two valued activities each week | Every visit | Completed today | Court work and letters to friends resumed; goal met |

## Goal progress

- Reduce PHQ-9 score from 14 to below 5 by the twelve-week review. In progress; target 2026-09-30. **S**
- Take sertraline as prescribed on at least six of seven days each week. In progress; target 2026-09-30. **S**
- Resume at least two valued activities each week, such as court work and letters to friends. Outcome by 2026-08-11: Resumed by the six-week visit. **S**

## Guideline basis

- VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022), United States Department of Veterans Affairs and Department of Defense
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge

## Follow-up

- Nurse telephone check with a PHQ-9 in about four weeks. Twelve-week depression review in seven weeks. Call the clinic or 988 at any time if his mood worsens or suicidal thoughts appear. **S**
- Next scheduled visit 2026-09-30: twelve-week depression care-plan review. **S**
